Free Trial

Elekta (OTCMKTS:EKTAY) Stock Rating Upgraded by Zacks Research

Elekta logo with Medical background

Key Points

  • Elekta has been upgraded from a "strong sell" rating to a "hold" rating by Zacks Research, amidst a consensus rating of "Reduce" from other analysts.
  • The company's stock opened at $5.25 and has a market capitalization of $1.93 billion, with a P/E ratio of 87.43.
  • Elekta reported earnings of $0.03 per share for the last quarter, with revenue of $379.64 million and is expected to post $0.36 EPS for the current fiscal year.
  • Five stocks we like better than Elekta.

Zacks Research upgraded shares of Elekta (OTCMKTS:EKTAY - Free Report) from a strong sell rating to a hold rating in a research note issued to investors on Tuesday,Zacks.com reports.

Several other equities analysts also recently issued reports on EKTAY. UBS Group began coverage on shares of Elekta in a report on Wednesday, September 3rd. They set a "sell" rating on the stock. Danske lowered Elekta to a "hold" rating in a research report on Tuesday, June 3rd. Three investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Elekta currently has a consensus rating of "Reduce".

Get Our Latest Stock Analysis on Elekta

Elekta Stock Up 1.8%

Elekta stock traded up $0.10 during trading hours on Tuesday, reaching $5.35. The stock had a trading volume of 1,320 shares, compared to its average volume of 4,251. The company has a market cap of $1.97 billion, a price-to-earnings ratio of 89.18 and a beta of 1.10. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.05 and a quick ratio of 0.82. The business's 50 day moving average price is $4.99 and its 200-day moving average price is $5.07. Elekta has a 52 week low of $4.36 and a 52 week high of $7.13.

Elekta (OTCMKTS:EKTAY - Get Free Report) last announced its earnings results on Thursday, August 28th. The company reported $0.03 EPS for the quarter. Elekta had a net margin of 1.40% and a return on equity of 11.49%. The business had revenue of $379.64 million during the quarter. Sell-side analysts anticipate that Elekta will post 0.36 EPS for the current year.

Elekta Dividend Announcement

The business also recently announced a dividend, which will be paid on Friday, September 26th. Shareholders of record on Tuesday, September 9th will be paid a $0.0744 dividend. The ex-dividend date of this dividend is Monday, September 8th. This represents a dividend yield of 289.0%. Elekta's dividend payout ratio (DPR) is 216.67%.

About Elekta

(Get Free Report)

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services.

Recommended Stories

Should You Invest $1,000 in Elekta Right Now?

Before you consider Elekta, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elekta wasn't on the list.

While Elekta currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.